
Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.

Targeting chronic myeloid leukemia stem cells with ERK5 pathway inhibitors
Vol 32, Issue 4S1, 2018
Abstract
Tyrosine kinase inhibitors (TKi) targeting BCR/ABL are very effective for the treatment of Chronic Myeloid Leukemia (CML). However, discontinuation and/or inefficacy on CML leukemia stem cells (LSC) may lead to relapse. To identify new druggable targets alternative to BCR/ABL, we investigated the role of the Extracellular signal-Regulated Kinase 5 (ERK5) pathway in CML LSC maintenance.
References
Supporting Agencies
Copyright (c) 2018 I Tusa, G Cheloni, M Poteti, A Gozzini, X Deng, N S Gray, S Li, P Dello Sbarba, E Rovida
This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Medical Genetics, University of Torino Medical School, Italy

Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy